Skeletal Dysplasia Drugs Market Trends

The increasing prevalence of skeletal dysplasia is a significant driver for market. The limited number of effective therapies currently available creates a significant need for new and improved treatments to manage rising cases & symptoms and improve patient outcomes.

• According to the Journal of Rare Diseases, in 2023, skeletal dysplasia represent approximately 5% of all congenital anomalies. Further, the report also stated that there has been a surge in the number of cases in the U.S. and other countries.
  
• Similarly, as per John Hopkins University report, in 2023, skeletal dysplasia is estimated to affect 2.4 per 10,000 births. The disease have significantly high frequency (11.5%) among children with short stature.
  
• Enhanced diagnostic tools such as advanced imaging techniques (MRI, CT scans) and genetic testing, have led to more accurate and earlier diagnosis of skeletal dysplasia. Greater awareness among healthcare providers and patients has resulted in more frequent identification and diagnosis of these conditions.
  
• Ongoing research and development efforts are focused on creating new drugs and therapies specifically targeting the underlying causes and symptoms of skeletal dysplasia. Innovations such as enzyme replacement therapy, gene therapy, and other targeted treatments are expanding the range of options available to patients, driving market growth.